Evidence-based · Educational only•
36+ Peptides indexed•
Free research library•
Free newsletter — subscribe below•
★ = FDA-approved medical indication•
Not medical advice — always consult a clinician•
Evidence-based · Educational only•
36+ Peptides indexed•
Free research library•
Free newsletter — subscribe below•
★ = FDA-approved medical indication•
Not medical advice — always consult a clinician•
Peptide Knowledge Center
All peptides

PT-141

Also known as: Bremelanotide / Vyleesi
FDA-Approved

Bremelanotide is a melanocortin receptor agonist (MC4R-preferring) approved for HSDD in premenopausal women.

Buy PT-141 on American Peptides

Affiliate link — we may earn a commission at no extra cost to you.

Overview

Bremelanotide is a melanocortin receptor agonist (MC4R-preferring) approved for HSDD in premenopausal women.

FDA Approval Status

Approved by the FDA for at least one medical indication (see approved uses below).

Mechanism of Action

Central melanocortin receptor agonism.

Current Research

RECONNECT trials.
Research strength: Strong

Potential Medical Uses

  • Acquired, generalized HSDD in premenopausal women

Potential Benefits

  • On-demand dosing

Known Side Effects

  • Nausea
  • Flushing
  • Injection-site reactions
  • Transient BP elevation

Contraindications

  • Uncontrolled hypertension
  • Cardiovascular disease

Drug Interactions

  • Oral naltrexone (reduced efficacy)

Administration Methods

  • Subcutaneous autoinjector

Half-life

~2.7 hours

Reconstitution

Prefilled autoinjector.

Storage & Handling

Room temperature per label.

References & Sources

Frequently Asked Questions

Information on this page is educational and general in nature. It is not medical advice. Consult a qualified healthcare professional before making any medical decisions.